Zhang SM, et al. - In resected non-small cell lung cancer (NSCLC), researchers sought to ascertain the predictive value of EGFR and KRAS mutations by analyzing data from studies assessing disease-free survival (DFS) and overall survival (OS) in resected NSCLC patients with EGFR or KRAS mutations identified from Internet databases. They performed a meta-analysis to calculate the pooled hazard ratio for DFS and OS. Overall, 9,635 patients from 32 studies were analyzed. A prolonged DFS and OS was seen among surgically treated NSCLC patients with EGFR mutations. In addition, in patients with resected NSCLC, worse DFS and OS were indicated to be predicted by KRAS mutations.